By R. Ivan. Biola University. 2019.
Shamefully discount 150 mg lyrica with amex, J&J (Janssen) and BI have not joined the savings party purchase lyrica 150mg line. Clinton Foundation (CHAI) and major generic manufacturers purchase 150 mg lyrica fast delivery. The median price paid for TDF+3TC+efavirenz (prequalified by WHO) in low-income countries in July 2014 was $100 per person per year for the fixed-dose combination buy lyrica 150 mg on line. Combinations with d4T (stavudine) and ddI (didanosine) have fallen off the pricing scales finally. Second-line regimens Second-line regimens are still significantly more expensive than first-line regimens in low- and middle-income countries. In 2014, the cost of a regimen of AZT+3TC+ atazanavir/r, is $243 in low-income countries and significantly higher in middle- income countries. Prices paid for second-line regimens can vary significantly between countries. In the UK, a study showed that first-line treatments can last 8 years or longer (UK Chic 2010). If ARV access in the developing world started in earnest in 2002 (without all the management and strategic tools of retention and adherence used in the North, like viral load measurements), we are beyond the 8-year mark. What to do with the people who need to move to a new regimen (whose number is growing now that everyone should be on treatment)? Of the regimens that fail, NNRTIs fail at a rate almost three times higher than the rate of PIs. Most people in resource-limited set- tings are on an NNRTI-containing regimen (nevirapine or efavirenz). MSF estimates that regimen failure is “largely under-diagnosed” due to limited lab facilities for viral load testing, which can only lead to resistance and harder-to-construct post-first-line regimens. How to expand treatment to more people plus switch those currently failing to a more expensive second-line regimen, all within a framework of cutting back on donor spending? As the absolute numbers of people who need access to second-line regimens continue to grow, addressing the high cost of second-line regimens will become increasingly important to ensure the cost-effective use of available resources. A third-line treatment can be up to 8 times as expensive as a second-line treatment. Obviously, management, retention and adherence issues need to be fully incorporated into care in order to keep everyone on treatments and help them not need to advance to more complicated and expensive regimens. Future Funding As funding stalls, major funders – US, UK, Netherlands, France, Germany, Norway and Sweden – are fatigued. The good news is that countries are now starting to help support their own programs, ranging from a little more than 40% in Sub-Saharan Africa to more than 95% in Latin America and the Caribbean (UNAIDS 2015). New strategies have to be developed – small taxes on currency transactions (Oxfam’s Robin Hood tax), an airline ticket tax, a Global Health charge on alcohol and tobacco consumption (Hill 2012) etc. Product(Red) is a fund-raising mechanism tied to the Global Fund that coordinates profits from sales from businesses, and has recently reached the $320 million mark. It is perhaps more important than ever that we all contribute, whether economically or advocacy-based, to be able to optimally treat everyone. Global access to HIV treatment 279 Europe gets involved The European Union can impact access to medicines for developing countries through its policies, legislation and bilateral and regional trade agreements. The EU can adopt appropriate measures to improve access to existing medical tools (medi- cines, diagnostics, vaccines) as well as stimulate the research and development of better tools for people in resource-starved countries. The Working Group on Innovation, Access to Medicines and Poverty-Related Diseases will create a mean- ingful dialogue between Members of the European Parliament, the European Commission, and civil society. The EP Working Group is working hard on not allow- ing TTIP to harm medicines and health access. From rhetoric to reality Successes in controlling the epidemic can be attributed to a comprehensive response and commitment from all sectors of society, according to on-the-ground experts in sub-Saharan Africa. Buy-in from the highest political offices is important in creating polices that place HIV on the national agenda. For instance, in Rwanda, all govern- ment departments were mandated to carry HIV messages over a long period, which helped stabilize spread of the disease. The Rwandan Minister of Health reminds us to include youth in the messaging. Although extensively reviewing the latest International AIDS Conference is impos- sible here, there was an effort to demonstrate the importance of including patients and their broader communities in the delivery of services (www. From the Vancouver 2015 consensus statement, “We call on leaders the world over to implement HIV science and commit to providing access to immediate HIV treatment to all people living with HIV. We call on donors and governments to use existing resources for maximum impact and to mobilize suf- ficient resources globally to support ARV access for all, UN 90/90/90 goals for testing, treatment and adherence, and a comprehensive HIV response. We call on clinicians to build models of care that move beyond the clinic to reach all who want and need ARVs. We call on civil society to mobilize in support of immediate rights-based access to treatment for all. Ukraine gives a positive spin on how to do it with combination prevention and substitution therapies. Educating politi- cal leadership in these countries (including Russia) is important since so few resources are allocated to fighting HIV. There may be some basic ingredients for “getting there”: • Cascading implementation structures from national to grassroots level • Ensuring increasing national government budget allocation to HIV responses while donors support ongoing gaps (ie, country ownership) • Mobilizing all sectors of society to play their part in HIV • Integrating principles of good governance from the outset to ensure accountabil- ity at all levels. The unconscionable health gap: a global plan for justice If the health gap is unfair and unacceptable, how can the international community be galvanized to make a genuine difference? A “global plan for justice” would be a voluntary compact between states and their partners. It would simply encourage the 280 ART WHO to exercise its constitutional powers and leadership. This global plan for justice would guarantee a universal package of essential services, comprising core compo- nents like essential vaccines and medicines, basic survival needs, and adaption to climate change (Gostin 2010). The amount of people who need access to ART in the next few years is clear – if 15 million people are treated, 22 million are not. We need to keep up the pressure on all actors – donor organizations as well as individual nations, manufacturers, health care workers and affected communities of all sizes – to do their part in order to provide the most current and useful prevention and treatment strategies to the adequate and most at-risk populations. In order to achieve this, we can not sit idly by and hope for the best – we must continue to push that boulder up the hill for as long as it takes so everyone who needs it has access to prevention including PrEP, treatment and care as early and for as long as necessary. References (because global access is a moving target, most references are web-based) Collaborative Group on HIV Drug Resistance and UK CHIC Study Group. Long-term probability of detecting drug- resistant HIV in treatment-naïve patients initiating combination antiretroviral therapy. The unconscionable health gap: a global plan for justice. Correcting globalization in health: transnational entitlements versus the ethical imper- ative of reducing aid-dependency. Financing of global health: tracking development assistance for health from 1990 to 2007. Country Planning for Maximum Impact, International AIDS Conference, MOSS01, July 22-27, 2012, Washington DC, USA. Reducing health inequities through action on the social determinants of health, http://apps. Management of Side Effects THOMAS BUHK UND CHRISTOPH D. SPINNER Antiretroviral Therapy (ART) has become more and more tolerable. Side effects has been become less frequent and less severe. While in the past up to 25% of ART disruption due to side effects were observed within the first year of ART (d’Arminio Monforte 2000, Yuan 2006), treatment cessation due to side effects has become less frequent (Carr 2009, Cooke 2014). Nevertheless side effects and tolerability play an important role within clinical care of HIV+ patients. Regular visits help to address this factor for improving treatment success.
The recommended dosage is 150 mg rifabutin 3x/week (EACS 2014) lyrica 75mg with visa, while recent data suggest under-dosing of rifabutin with this regime purchase lyrica 150 mg with visa. US guidelines recommend daily rifabutin 150 mg with monitoring for neutropenia and uveitis (OARAC 2015) buy 150 mg lyrica otc. Efavirenz (standard dose) can also be combined with rifabutin (450 mg once daily) purchase 150 mg lyrica free shipping, which has less cytochrome P450 3A-inducing potential (EACS 2014). Nevirapine, rilpivirine and etravirine are not recommended in combination with rifamycins. Raltegravir, metabolized via the UDP-glucuronosyltransferase, is a good and safe alter- native. Raltegravir 400 mg BID and 800 mg BID proved to be a safe and efficacious treatment option for HIV-TB coinfection in a small Phase II study, the best available evidence for its use with rifampicin pending a Phase III trial (Grinszteijn 2014). A combination of 3–4 NRTIs (AZT, ABC, 3TC ± TDF) could represent a short-term option for patients with viral load <100,000 copies/ml until TB treatment with RIF is completed. With rare exceptions, other regimens may include T-20 as it has no interactions with rifamycins (Boyd 2003). There are limited data about the combination of rifampicin and some other anti- retroviral agents like elvitegravir, cobicistat, rilpivirine, etravirine, tipranavir and maraviroc. Maraviroc should only be given under close observation. No significant interactions were reported with tenofovir (Droste 2005). A Phase I pharmacokinetic study in healthy volunteers suggested that dolutegravir should be dosed twice daily (50 mg BID) in combination with rifampicin (600 mg QD), while the standard dose (50 mg QD) can be combined with rifabutin (300 mg QD) (Dooley 2013). Bedaquiline use with CYP3A4 inducers and inhibitors is not recommended (van Opportunistic Infections (OIs) 363 Heeswijk 2014). Clinical data on interaction of delamanid with antiretroviral drugs are not yet available. Adherence to therapy is difficult due to the large number of ART and anti-tubercu- losis drugs administered simultaneously and their overlapping toxicities. The most decisive determinant for the success of TB treatment is good drug adherence for the entire duration of therapy. When compliance is impaired, the development of drug resistance and relapses are common. Therefore, WHO recommends that all patients with TB should be enrolled in directly observed therapy programs. Immune reconstitution inflammatory syndrome (IRIS) A critical question is the timing of ART initiation in coinfected patients as the timing of ART is closely related to the risk of occurrence of TB associated immune recon- stitution inflammatory syndrome (IRIS). TB-associated IRIS has been reported to occur on average in 15% of severely immunocompromised patients although inci- dence data are highly variable (Müller 2010). In paradoxical TB associated IRIS patients are diagnosed with active TB and initially show a positive treatment response. However, within three months of initiation of ART there is clinical worsening (i. It has been suggested that an acute exacerbation of a TH1 immune response against mycobacterial antigens is responsible for the paradoxical reaction in ART experi- enced HIV/MTB coinfected patients (Bourgarit 2006). In the so-called unmasking TB-IRIS active TB is not diagnosed at the initiation of ART, but is diagnosed within 3 months of initiation (Meintjes 2008). It is thought that the recovery of pathogen-specific immune responses during the initial months of ART trigger the unmasking of a subclinical disease. Screening strategies for under- lying TB need to be carefully emphasized in order to prevent severe unmasking manifestations. The only randomized controlled trial for the management of paradoxical TB associ- ated IRIS used 1. It showed a significant reduction in paradoxical IRIS-related hospital days and outpatient procedures (Meintjes 2010). During TB-associated IRIS, both ART and TB therapy should be continued (OARAC 2015). Two trials investigating meloxicam and prednisolone for the prevention of TB-IRIS are ongoing. As in patients with TB meningitis and HIV infection the risk of IRIS-related mortality is high, and it is recommended to start ART in TB meningitis patients 8 weeks after starting the TB therapy (Törok 2011). Adverse events The most frequent and significant adverse events of TB drugs are listed in Table 1. INH should routinely be coadministered with prophylactic pyridoxine (vitamin B6) to prevent peripheral polyneuropathy. Before and during therapy with EMB, colour vision should be examined and moni- tored as this drug may affect the optic nerve. Dosages of EMB and PZA need to be adjusted in patients with impaired renal function. Drug-induced liver injury (DILI) is a common problem in the management of HIV/TB coinfection. A consensus state- ment of the South African HIV Society gives helpful advice in the management of DILI (Jong 2013). Monthly audiometric monitoring should be performed when streptomycin or second-line injectables are used. Following the start of TB therapy, liver enzymes, 364 AIDS serum creatinine, electrolytes and full blood count should be monitored on a regular basis (e. A mild polyarthralgia can be treated with allopurinol and non-steroidal antiphlogistic drugs. Arthralgia can also be induced by RIF and rifabutin. Therapy of drug resistant TB with nephrotoxic injectables (amikacin, kanamycin, capreomycin, streptomycin) in combination with tenofovir should be avoided (Kenyon 2011). Data on use of bedaquiline and delamanid in patients on ART are rare. QTc interval monitoring is essential for both drugs, par- ticular in combination with flouroquinolones, clofazime and clarithromycin (WHO 2013, WHO 2014b). Patients who exhibit severe adverse events should always be hospitalized for diag- nosis and treatment. Drugs thought to be responsible for a given adverse event ought to be discontinued. If visual disturbance occurs on EMB, renal failure or shock or thrombocytopenia on RIF and vestibular dysfunction on SM/SLID therapy, re-expo- sure to these agents must be avoided. Other drugs can be reintroduced one by one when symptoms resolve, beginning with the drug that is least likely to cause the adverse event. All drugs should be restarted at low doses and doses should be increased stepwise (Table 3). When no adverse effects occur after 3 days, additional drugs can be added. The drug that is most likely to be responsible for an adverse effect should be the last one to be restarted if no alternative is available. When second-line drugs are used it is usually necessary to prolong the standard treatment duration (WHO 2014c). Table 3: Re-introduction of TB drugs following drug-related adverse event(s) Drug Day 1 Day 2 Day 3 INH 50 mg 300 mg 5 mg/kg/day (max 300 mg/day) RIF 75 mg 300 mg 10 mg/kg/day (max 600 mg/day) PZA 250 mg 1,000 mg 25 mg/kg/day (max 2 g/day) EMB 100 mg 500 mg 25 mg/kg/day for 2 months then 15 mg/kg/day Streptomycin 125 mg 500 mg 15 mg/kg/day (max 1 g/day) References Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. Integration of antiretroviral therapy with tuberculosis treatment. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. Response to treatment, mortality, and CD4 lymphocyte counts in HIV- infected persons with tuberculosis in Abidjan, Cote d’Ivoire. Aichelburg MC, Armin Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon- release assay in HIV-1-infected individuals. BHIVA: BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012 (updated November 2013). Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
How did you circumnavigate the obstacles that visibly impede fluent speech in adults? From what we saw in the Listening chapter discount lyrica 150mg amex, part of the solution was to postpone speech buy 75 mg lyrica with amex, and to just listen to the sounds of the world lyrica 150mg discount. It took approximately 5 to 7 months before you started to babble and utter meaningless sounds such as ‘ba-ba- ba-ba-ba’ discount lyrica 150 mg line, ‘ka-bu-ba-da-mi’; and only when you reached the age of 12 months were you ready to experiment with real words and two-word sentences, generally in order to express desire: ‘More juice’, ‘Want cookie’. You took your time before wrapping your baby thoughts in chunks of language. They made it easier to let sounds come into your brain than to let them out. To let human speech in, all you need is an eardrum, three tiny bones in your middle ear, and the so-called cochlea. These structures amplify the sounds, and transduce them to electrical signals for the brain where speech segmentation and interpretation immediately ensue. This is a straightforward process, and apart from your ears and your brain, nothing else is involved. In comparison, speaking requires sophisticated mechanics. To proclaim the resolutions of your brain to the world, you have to co-ordinate dozens of muscles in your larynx, pharynx, neck, cheeks, mouth, and tongue. Putting all these pieces into the perfect position in a minimum amount of time is a remarkable acrobatic performance, and even children need years of exercise. In fact, only at around the age of ten do they start speaking like adults (Figure 5. From the very beginning, comprehension has a head start over speech production – when you stutter your first barely intelligible sounds, you already possess a vast passive repertoire of hundreds of words. The disparity between good language comprehension and poor language production usually persists Web: TheWordBrain. Many people may one day read Thomas Mann, Hemingway, or Voltaire, but only a few will develop their writing skills. Speaking skills have another disturbing characteristic: they are subject to heavy erosion. Stop speaking a second language for a decade or more, and even simple words such as ‘Goodbye’ are suddenly irretrievable. At the same time, listening and reading skills are hardly impaired. It seems as if once you acquire the ability to understand with native-like proficiency, you have acquired it for life, like riding a bicycle. The speaking abilities, on the contrary, would need continuous stimulation to be maintained. Unless you are incorrigibly logorrheic, listening is the predominant function mode of your word brain. As soon as you find yourself in a group of at least three people, the odds are that you will listen rather than speak. The bigger the group, the smaller your contribution. In some situations – at school, university, or during meetings at work – you could listen for hours, and nobody would expect you to contribute more than a word or two. As a result of years of listening, the part of your word brain that processes sounds is better trained than the part that produces speech. The words put into your brain are more diverse than the words coming out of it. You have only one life to tell – your own – while your co-humans make you listen to hundreds of different lives in different places and in different circumstances. You know words annunciated by fascists, fundamentalists and populists that you wouldn’t want to ever pass your lips. You know hundreds or thousands of words from listening to priests, rabbis, and imams, but, again, you would not want to use them yourself because, as a scientist, you feel that God and the gods exist because our ancestors had the wisdom to create them. This list can go on and on, including Print: Amazon. Because of the huge variability of human biographies – sometimes disgustingly ugly, but most often creative, stimulating, and refreshing – you know thousands of words you will never utter. What you know of the world is more than what you can say about it. Imagine living the life of a distant ancestor 100,000 years ago. How would you value listening skills with respect to speaking skills? What could be more useful for survival, the correct interpretation of the sounds around you – ‘Is that a wolf? But this discussion is beyond the frame of a short language guide. I promised you that you would partly avoid producing stuttering and ungraceful speech. If you are abroad, every day presents hundreds of opportunities to speak to friends and strangers. If, instead, you are at home, listen to your favourite language CDs and repeat the now familiar words and sentences. Imitate the sounds, in particular the length of the vowels and the melody of the sentences. Later, repeat the sentences in real-time, with an interval of just one second. You will be amazed at how the sounds soon start to come out of your mouth. Repeating the lessons of your language manuals will take you some weeks. Again, don’t feel uncomfortable repeating a th language CD for the 14 time. Thereafter, use the same procedure – listening to and reproducing speech with a one- second interval – with sentences from other sources such as podcasts, audio books, or TV. In the beginning, real-life speech Web: TheWordBrain. Have you noticed that I have again limited free expression? I suggested that you repeat the sentences of language manuals, TV, and audio books. In other words, I recommended that you do not translate from your native language. Translations are risky for a language novice because they generate a large number of errors. You might get accustomed to these errors and end up being unable to say what is right and what is wrong. Whenever possible, it is thus preferable that you use words and sentences that you have already heard being said by other people. At this early stage, don’t be ashamed to be a parrot. While transmuting into a parrot is generally feasible, another fundamental conversion may be out of reach for some individuals. Imagine that you step into one of the Paris boulevard restaurants and order an overprized micro-bottle of mineral water and a dish of spaghetti bolognese. The art of al-dente cooking hasn’t arrived in France yet. To be honest, you didn’t look like a weathered adult, in control of life, family and career, but rather like a clumsy and gawky creature or bungling adolescent, struggling to find your way in the world. That’s the way it is: during your first steps in a new language, at best, you regress to a kind of cutesy childhood, at worst, you are a weirdo, a nobody, an untouchable. Some people perceive this as a high price for familiarising themselves with other languages and decide that they are not willing to pay the price. They don’t want, at any cost, to look clumsy, awkward, or inept.
Only two published abstracts examined the general efficacy of lubiprostone in elderly patients generic lyrica 75 mg amex. Tables 31 and 32 summarize the evidence profiles for the treatment of chronic constipation and IBS-C with constipation drugs for subgroups 150 mg lyrica. Detailed assessment Sex Chronic constipation We did not find any studies published as full text articles specifically designed to examine the general or comparative efficacy of docusate calcium cheap lyrica 150 mg on-line, docusate sodium generic lyrica 150mg on line, lactulose, lubiprostone, PEG 3350, psyllium, or tegaserod for chronic constipation in men versus women. The available direct evidence is limited to 28 one pooled data analysis comparing lubiprostone and placebo. This published abstract compared the efficacy of lubiprostone and placebo for treating chronic 28 constipation in men versus women. Men and women both responded favorably to lubiprostone experiencing approximately twice as many spontaneous bowel movements (SBMs) per week as placebo patients. Response rates were similar in males and females Constipation Drugs Page 63 of 141 Final Report Drug Effectiveness Review Project treated with lubiprostone (5. This study was published as an abstract only; the information presented is insufficient to critically appraise the underlying methods of this study and draw firm conclusions. For example, in two RCTs 37 38 on tegaserod 90% and 86% of patients were female. In general, effect sizes of treatment responses in such populations did not appear to be substantially different from those in populations with higher proportions of male participants. However, no firm conclusions about any differences in efficacy and safety between men and women can be drawn based on such assessments. Constipation associated with IBS We did not find any studies published as full text articles specifically designed to examine the general efficacy of docusate calcium, docusate sodium, lactulose, lubiprostone, PEG 3350, psyllium, or tegaserod for IBS-C in men versus women. Both studies provide evidence that tegaserod provides a rapid and sustained improvement in IBS-C symptoms in female patients. Tegaserod has never had FDA approval for the treatment of IBS-C in males, and evidence on the general efficacy of tegaserod in men is sparse. Only three studies enrolled males and females with IBS-C (males comprised 12%-17% of patients). From these studies it remains unclear, however, whether any differences in efficacy between men and women existed. We did not find any studies specifically designed to examine the comparative efficacy of docusate calcium, docusate sodium, lactulose, lubiprostone, PEG 3350, psyllium, or tegaserod for chronic constipation in men versus women. Age Chronic constipation We did not find any studies published as full text articles specifically designed to examine the general efficacy of docusate calcium, docusate sodium, lactulose, lubiprostone, PEG 3350, psyllium, or tegaserod for chronic constipation in elderly populations. The available evidence is limited to two pooled data 26, 27 analyses comparing lubiprostone and placebo. Constipation Drugs Page 64 of 141 Final Report Drug Effectiveness Review Project 26, 27 Two published abstracts examined the efficacy of lubiprostone in patients > 65 years. In each study, data were pooled from three RCTs to provide an adequate pool of elderly subjects for analysis. Lubiprostone was well tolerated by elderly subjects in both studies. With regard to long-term efficacy, in the first pooled analysis, improvements in assessments of constipation severity, abdominal bloating, and abdominal discomfort, were all statistically significant at all post baseline time points from week 1 to 27 week 48 in both elderly and non-elderly subgroups (P < 0. In the second study, mean changes from baseline in SBM rates were significantly improved among lubiprostone elderly subjects compared to 26 their placebo counterpoarts during weeks 1,2, and 4 (P < 0. However, because these studies were published as abstracts only, the available information is insufficient to critically appraise the underlying methods and draw firm conclusions. We did not find any studies specifically designed to examine the comparative efficacy of docusate calcium, docusate sodium, lactulose, lubiprostone, PEG 3350, psyllium, or tegaserod. Constipation associated with IBS We did not find any evidence on differences of efficacy and harms of constipation drugs based on age. Race or Ethnicity We did not find any evidence on differences of efficacy and harms of constipation drugs for the treatment of chronic constipation or constipation associated with IBS based on race or ethnicity. Co-morbidities We did not find any evidence on differences of efficacy and harms of constipation drugs for the treatment of chronic constipation or constipation associated with IBS based on co-morbidities. Constipation Drugs Page 65 of 141 Final Report Drug Effectiveness Review Project Table 31. Evidence profile ofth e generalefficacy and h arm s ofconstipationdrugs forch ronicconstipationand IB S-C insubgroups Evidence Profile:G eneralefficacy and h arm s ofconstipationdrugs forch ronicconstipationand IB S-C insubgroups N o. Evidence profile ofth e com parative efficacy and h arm s ofconstipationdrugs forch ronicconstipation and IB S-C insubgroups Evidence Profile:C om parative efficacy and h arm s ofconstipationdrugs forch ronicconstipationand IB S-C insubgroups N o. Multiple drugs are commonly used to treat these conditions. Many of these drugs are available over the counter and have been available for decades. Despite the high 2, 70 prevalence and the enormous socioeconomic burden associated with these conditions, results of our review highlight that for most treatments, objective evidence from well-conducted studies on efficacy and safety is largely missing. For medications that are considered first-line treatments such as bulking agents or stool softeners, solid evidence is missing or of questionable methodological quality. Even for drugs that are considered first- line prescription medications such as osmotic laxatives, the evidence is sparse and fraught with severe methodological problems. Although we revised our eligibility criteria while conducting this report to include any controlled prospective study, regardless of design, we could not find any studies on the efficacy and safety of docusate calcium, docusate sodium, and lactulose for the treatment of chronic constipation or IBS-C. A systematic review reported some low-quality evidence supporting the use of lactulose for occasional 71 constipation. However, these findings cannot be extrapolated to populations with chronic constipation or IBS-C. Although multiple studies support the general efficacy of PEG 3350 for the treatment of chronic constipation in adults and children, most of them are short-term (i. The general safety evidence from three RCTs (1 fair and 2 poor quality) suggests PEG 3350 is well tolerated with only minor adverse events (nausea, gas, cramps, and diarrhea). High quality evidence supports the efficacy of tegaserod for the treatment of chronic constipation in adults and children and IBS-C. However, tegaserod has been taken off the market because of safety concerns due to a recent analysis reporting an increased risk of cardiovascular events. Several previous studies on the general safety and tolerability of tegaserod consistently reported an increased incidence of diarrhea compared to placebo. At present it remains unclear whether tegaserod will be re-approved for selected indications in the future. Constipation Drugs Page 68 of 141 Final Report Drug Effectiveness Review Project Multiple RCTs provide evidence on the efficacy and safety of lubiprostone for the treatment of chronic constipation. However, all these trials have been published as abstracts only. Therefore, no firm conclusions about the net benefits or harms of lubiprostone for the treatment of chronic constipation can be drawn. With regard to tolerability and safety, the 23, 54, 55, 72 incidence of nausea was consistently higher in patients on lubiprostone than on placebo. In phase III trials, 10% of patients on lubiprostone discontinued treatment because of adverse events, mainly 71 gastrointestinal symptoms. Evidence comparing one agent with another is similarly sparse. For the treatment of chronic constipation 42 in adults we found three head-to-head trials comparing the efficacy of docusate sodium with psyllium, 43 45 lactulose with PEG 3350, and PEG 3350 with psyllium. These studies are all less than 4 weeks of duration and all have considerable methodological limitations. Therefore, no firm conclusions can be drawn about the comparative efficacy of these drugs. In addition, it should be noted that only one study compared medications from the same groups (i. The other two studies compared medications from different groups i. In clinical practice, these medications are often used together since they work in different ways to improve bowel movements. For comparative safety in adults 43 we found four head-to-head trials comparing PEG 3350 with lactulose, lactulose with psyllium (2 65, 66 45 trials), and PEG 3350 with psyllium.
9 of 10 - Review by R. Ivan
Votes: 99 votes
Total customer reviews: 99